Online inquiry

IVTScrip™ mRNA-Anti-MS4A1, AT-004(Cap 0, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ3351MR)

This product GTTS-WQ3351MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets MS4A1 gene. The antibody can be applied in Canine B-cell lymphoma research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Caninized
RefSeq NM_001048028.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 485430
UniProt ID Q3C2E2
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MS4A1, AT-004(Cap 0, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ3351MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2005MR IVTScrip™ mRNA-Anti-INSR, AGT-181(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AGT-181
GTTS-WQ6739MR IVTScrip™ mRNA-Anti-EGFR, DS 992(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA DS 992
GTTS-WQ12928MR IVTScrip™ mRNA-Anti-MUC1, PankoMab(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA PankoMab
GTTS-WQ10446MR IVTScrip™ mRNA-Anti-MSTN, LY-2495655(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA LY-2495655
GTTS-WQ8306MR IVTScrip™ mRNA-Anti-GLP1R, HM-12525A(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA HM-12525A
GTTS-WQ5822MR IVTScrip™ mRNA-Anti-CD3E, ChAglyCD(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ChAglyCD
GTTS-WQ2685MR IVTScrip™ mRNA-Anti-SOST, AMG 785 (Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA AMG 785
GTTS-WQ14898MR IVTScrip™ mRNA-Anti-stx2 A-subunit, Shigamabs®(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA Shigamabs®
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW